Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disulfiram + lomustine
- Development stage
- Discontinued
- Lead developer
- NextSource Biotechnology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of disulfiram and lomustine that has been investigated for the treatment of glioblastoma. Lomustine is an alkylating agent that interferes with cancer cell growth by disrupting DNA, while disulfiram is primarily used to treat alcohol addiction but has been studied for potential anticancer properties. The combination was investigated based on preclinical evidence suggesting synergistic effects, particularly when disulfiram is combined with copper supplementation.
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)DNALY96 (Myeloid differentiation factor 2)
Beyond the preview
Go deeper on disulfiram + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disulfiram + lomustine.